Impact of left ventricular geometry on prognosis in hypertensive patients with left ventricular hypertrophy (the LIFE study)

European Journal of Echocardiography

Volumn 9, Issue 6, 2008, Pages 809-815

  Gerdts, Eva ^a,b   Cramariuc, Dana ^a,b   De Simone, Giovanni ^c   Wachtell, Kristian ^d   Dahlöf, Björn ^e   Devereux, Richard B ^f  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c FEDERICO II UNIVERSITY HOSPITAL   (Italy)

^d Rigshospitalet   (Denmark)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Atenolol; Hypertension; Left ventricular geometry; Left ventricular hypertrophy; Losartan

Indexed keywords

ATENOLOL; LOSARTAN;

ADULT; AGED; ARTICLE; BODY SURFACE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOPPLER ECHOCARDIOGRAPHY; DOUBLE BLIND PROCEDURE; FEMALE; HEART DEATH; HEART INFARCTION; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE WALL; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; STROKE;

AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; ATENOLOL; FEMALE; HEART VENTRICLES; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LOSARTAN; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES;

EID: 54949108283     PISSN: 15252167     EISSN: 15322114     Source Type: Journal    
DOI: 10.1093/ejechocard/jen155     Document Type: Article

References (35)

1. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991;114:345-52.
2. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;332:1561-6.
3. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Battistelli M, Bartoccini C et al. Adverse prognostic significance of concentric remodeling of the left ventricle in hypertensive patients with normal left ventricular mass. J Am Coll Cardiol 1995;25:871-8.
4. Muiesan ML, Salvetti M, Monteduro C, Bonzi B, Paini A, Viola S et al. Left ventricular concentric geometry during treatment adversely affects cardiovascular prognosis in hypertensive patients. Hypertension 2004;43:731-8.
5. Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004;292:2350-6.
6. Devereux RB, Bella J, Boman K, Gerdts E, Nieminen MS, Rokkedal J et al. Echocardiographic left ventricular geometry in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE study. Blood Press 2001;10:74-82.
7. Dahlöf B, Devereux RB, Julius S, Kjeldsen SE, Beevers G, de Faire U et al. The Losartan Intervention for Endpoint Reduction in Hypertension study. Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Hypertension 1998;32:989-97.
8. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002;359:995-1003.
9. Devereux RB, Dahlöf B, Gerdts E, Boman K, Nieminen MS, Papademetriou V et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 2004;110:1456- 62.
10. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440-63.
11. Gutgesell HP, Paquet M, Duff DF, McNamara DG. Evaluation of left ventricular size and function by echocardiography. Results in normal children. Circulation 1977;56:457-62.
12. Reichek N, Devereux RB. Reliable estimation of peak left ventricular systolic pressure by M-mode echographic-determined end-diastolic relative wall thickness: identification of severe valvular aortic stenosis in adult patients. Am Heart J 1982;103:202-3.
13. Teichholz LE, Kreulen T, Herman MV, Gorlin R. Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence of absence of asynergy. Am J Cardiol 1976;37:7-11.
14. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986;57:450-8.
15. Palmieri V, Dahlöf B, DeQuattro V, Sharpe N, Bella JN, de Simone G et al. Reliability of echocardiographic assessment of left ventricular structure and function: the PRESERVE study. Prospective Randomized Study Evaluating Regression of Ventricular Enlargement. J Am Coll Cardiol 1999;34:1625-32.
16. Palmieri V, de Simone G, Arnett DK, Bella JN, Kitzman DW, Oberman A et al. Relation of various degrees of body mass index in patients with systemic hypertension to left ventricular mass, cardiac output, and peripheral resistance (The Hypertension Genetic Epidemiology Network Study). Am J Cardiol 2001;88:1163-8.
17. Roman MJ, Pickering TG, Schwartz JE, Pini R, Devereux RB. Relation of arterial structure and function to left ventricular geometric patterns in hypertensive adults. J Am Coll Cardiol 1996;28:751-6.
18. de Simone G, Devereux RB, Roman MJ, Ganau A, Saba PS, Alderman MH et al. Assessment of left ventricular function by midwall fractional shortening/ end-systolic stress relation in human hypertension (published erratum appears in J Am Coll Cardiol 1994;24:844). J Am Coll Cardiol 1994;23:1444-51.
19. Gaasch WH, Zile MR, Hoshino PK, Apstein CS, Blaustein AS. Stress-shortening relations and myocardial blood flow in compensated and failing canine hearts with pressure-overload hypertrophy. Circulation 1989;79:872-83.
20. Lebowitz NE, Bella JN, Roman MJ, Liu JE, Fishman DP, Paranicas M et al. Prevalence and correlates of aortic regurgitation in American Indians: the Strong Heart Study. J Am Coll Cardiol 2000;36:461-7.
21. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-53.
22. WHO Study Group. Diabetes Mellitus (technical report series 727). Geneva: WHO; 1985.
23. Jensen JS, Clausen P, Borch-Johnsen K, Jensen G, Feldt-Rasmussen B. Detecting microalbuminuria by urinary albumin/creatinine concentration ratio. Nephrol Dial Transplant 1997;12:6-9.
24. Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation 1991;83:356-62.
25. Snapinn SM, Jiang Q, Iglewicz B. Illustrating the impact of a time-varying covariate with an extended Kaplan-Meier estimator. Am Statistician 2005;59:301-7.
26. Mathew J, Sleight P, Lonn E, Johnstone D, Pogue J, Qilong Y et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 2001;104:1615-21.
27. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and prediction of major cardiovascular events. JAMA 2004;292:2343-9.
28. Pierdomenico SD, Lapenna D, Bucci A, Manente BM, Cuccurullo F, Mezzetti A. Prognostic value of left ventricular concentric remodeling in uncomplicated mild hypertension. Am J Hypertens 2004;17:1035-9.
29. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I et al. Prognostic value of left ventricular mass and geometry in systemic hypertension with left ventricular hypertrophy. Am J Cardiol 1996;78:197-202.
30. Devereux RB, Roman MJ, Palmieri V, Okin PM, Boman K, Gerdts E et al. Left ventricular wall stresses and wall stress-mass-heart rate products in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention for Endpoint reduction in hypertension. J Hypertens 2000;18:1129-38.
31. de Simone G, Devereux RB, Roman MJ, Ganau A, Saba PS, Alderman MH et al. Assessment of left ventricular function by midwall fractional shortening/ end-systolic stress relation in human hypertension. J Am Coll Cardiol 1994;23:1444-51.
32. Hasebe N, Shen YT, Kiuchi K, Hittinger L, Bishop SP, Vatner SF. Enhanced postischemic dysfunction selective to subendocardium in conscious dogs with LV hypertrophy. Am J Physiol 1994;226:H702-13.
33. Galderisi M, de Simone G, Cicala S, De Simone L, D'Errico A, Caso P et al. Coronary flow reserve in hypertensive patients with appropriate or inappropriate left ventricular mass. J Hypertens 2003;21:2183-8.
34. Kozakova M, de Simone G, Morizzo C, Palombo C. Coronary vasodilator capacity and hypertension-induced increase in left ventricular mass. Hypertension 2003;41:224-9.
35. Dahlöf B, Burke TA, Krobot K, Carides GW, Edelman JM, Devereux RB et al. Population impact of losartan use on stroke in the European Union (EU): Projections from the Losartan Intervention for Endpoint reduction in hypertension (LIFE) study. J Hum Hypertens 2004;18:367-73.